Carl Crysler

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

Carl L. Manthey, Dana L. Johnson, Carl R. Illig et al. · Molecular Cancer Therapeutics · 2009 · 107 citations

Medicine, Oncology, Pharmacology +17

Design, Synthesis, and Biological Evaluation of Novel Potent and Selective α_vβ₃/α_vβ₅ Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core

Juan Marugán, Carl L. Manthey, Beth Anaclerio et al. · Journal of Medicinal Chemistry · 2005 · 68 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Modification of the Fc Region of a Primatized IgG Antibody to Human CD4 Retains Its Ability to Modulate CD4 Receptors but Does Not Deplete CD4+ T Cells in Chimpanzees

Roland Newman, Kandasamy Hariharan, Mitchell E. Reff et al. · Clinical Immunology · 2001 · 64 citations

Life Sciences, Cell Biology, Immunology +11

The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitors

K.J.M. Moriarty, Holly K. Koblish, Thomas Garrabrant et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +11

7-Fluoroindazoles as Potent and Selective Inhibitors of Factor Xa

Yu‐Kai Lee, Daniel J. Parks, Tianbao Lu et al. · Journal of Medicinal Chemistry · 2007 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9